hepat
b
viru
hbv
infect
consid
major
public
health
problem
worldwid
signific
number
report
nosocomi
occup
outbreak
report
systemat
investig
hbv
stabil
suscept
differ
antisept
reveal
hbv
infect
stabl
halflif
day
infect
bare
reduc
month
differ
alcohol
commerci
avail
hand
antisept
virucid
effect
hbv
propos
strict
complianc
establish
hygien
guidelin
mandatori
avoid
prevent
hbv
infect
hepat
b
viru
hbv
infect
sever
health
burden
approxim
billion
infect
peopl
million
chronic
infect
carrier
hbv
major
caus
chronic
liver
diseas
primari
caus
agent
hepatocellular
carcinoma
respons
death
worldwid
annual
despit
avail
vaccin
drug
chronic
hepat
b
still
incur
diseas
hbv
small
envelop
hepatotrop
dna
viru
belong
famili
hepadnavirida
viru
highli
contagi
circul
infecti
particlesml
blood
given
fact
healthcar
worker
constant
risk
acquir
hbv
infect
occup
exposur
moreov
nosocomi
transmiss
hbv
increas
number
outbreak
report
worldwid
past
year
common
transmiss
pathway
hbv
includ
use
multidos
vial
dental
biopsi
equip
dialysi
unit
contamin
fingerstick
devic
acupunctur
needl
endoscop
unsaf
surgic
inject
procedur
reus
syring
owe
lack
appropri
cell
cultur
model
suscept
hbv
infect
evidencebas
guidelin
prevent
manag
occup
exposur
incomplet
base
mainli
studi
duck
hepat
b
viru
dhbv
surrog
viru
recent
discoveri
na
taurochol
cotransport
polypeptid
ntcp
crucial
hbv
cell
entri
factor
open
door
new
avenu
investig
ntcpoverexpress
hepatoma
cell
acquir
suscept
hbv
infect
system
enabl
us
systemat
address
environment
stabil
hbv
differ
temperatur
ex
vivo
suscept
variou
type
alcohol
routin
use
commerci
avail
hand
antisept
furthermor
test
hand
hygien
formul
recommend
world
health
organ
hbv
compar
analysi
envelop
virus
result
use
defin
rigor
disinfect
protocol
prevent
nosocomi
occup
transmiss
hbv
futur
addit
materi
method
pleas
refer
supplementari
materi
hbv
particl
produc
cell
line
harbor
overlength
hbv
genom
control
tetracyclinerepress
promot
element
tetoff
system
product
process
describ
elsewher
briefli
cell
cultur
dulbecco
modifi
eagl
supplement
fetal
bovin
serum
fb
uml
penicillin
streptomycin
geneticin
insulin
hydrocortison
hemisuccin
tetracyclin
week
reach
cell
confluenc
tetracyclin
remov
medium
induc
viru
product
cell
cultur
supernat
collect
weekli
filter
millipor
steril
vacuum
filter
store
investig
effect
differ
temperatur
hbv
infect
viral
suspens
expos
differ
temperatur
indic
time
point
polymeras
chain
reaction
tube
eppendorf
germani
use
takara
thermal
cycler
b
r
e
f
r
e
p
r
author
publish
oxford
univers
press
infecti
diseas
societi
america
open
access
articl
distribut
term
creativ
common
attributionnoncommercialnoderiv
licenc
http
creativecommonsorglicens
permit
noncommerci
reproduct
distribut
work
medium
provid
origin
work
alter
transform
way
work
properli
cite
commerci
reus
pleas
contact
journalspermiss
oupcom
doi
dice
touch
takara
australia
heat
treatment
sampl
immedi
kept
ice
infect
cell
examin
impact
differ
ph
valu
solut
differ
ph
valu
prepar
describ
elsewher
viru
incub
differ
solut
minut
volum
ratio
viral
suspens
immedi
serial
dilut
dulbecco
modifi
eagl
medium
titrat
micropl
product
hbv
particl
human
hepatoma
cell
line
use
result
gener
hbv
infecti
particl
titer
median
tissu
cultur
infecti
dose
tcid
ml
viru
suspens
basi
conduct
viral
stabil
quantit
suspens
test
biocid
experi
perform
presenc
peg
enhanc
bind
hbv
particl
enabl
noninfecti
virion
enter
target
cell
first
evalu
hbv
stabil
differ
temperatur
incub
cell
culturederiv
hbv
particl
day
subsequ
infect
determin
inocul
naiv
cell
hbv
infect
rate
determin
immunofluoresc
analysi
interestingli
chang
infect
observ
minor
reduct
determin
day
room
temperatur
figur
sampl
store
hbv
infect
rate
reduc
timedepend
manner
howev
reach
inhibit
infect
day
next
longterm
stabil
hbv
assess
incub
viru
day
remark
hbv
infect
remain
stabl
day
incub
minor
reduct
approxim
figur
even
day
reduct
could
observ
note
number
infecti
particl
detect
day
approxim
detect
limit
assay
cutoff
tcid
ml
summari
result
indic
high
environment
stabil
hbv
suspens
surviv
time
sever
week
room
temperatur
hbv
particl
infect
host
circul
presenc
serum
effect
healthi
human
serum
hbv
stabil
analyz
incub
viral
particl
room
temperatur
day
compar
hbv
incub
side
side
fb
addit
human
serum
reduc
hbv
infect
time
compar
find
incub
fb
figur
next
impact
chang
ph
viral
stabil
test
incub
hbv
ph
minut
afterward
viral
titer
determin
limit
dilut
assay
demonstr
hbv
infect
affect
ph
figur
ethanol
common
activ
ingredi
commerci
alcoholbas
antisept
disinfect
use
healthcar
system
determin
efficaci
differ
alcohol
hbv
infect
hbv
incub
minut
figur
minut
figur
ethanol
concentr
rang
ethanol
concentr
requir
hbv
inactiv
irrespect
exposur
time
effect
alcohol
inactiv
hbv
reduc
viral
titer
undetect
level
concentr
exposur
minut
figur
case
incub
hbv
alcohol
led
reduct
infect
independ
incub
period
complet
abrog
infect
hbv
particl
necessari
longer
incub
time
minut
result
higher
inactiv
level
figur
conclus
hbv
demonstr
highest
suscept
ethanol
alcohol
concentr
requir
inactiv
hbv
particl
test
effect
alcohol
stabil
hbv
next
evalu
commerci
avail
hand
disinfect
sterillium
classic
pure
manorapid
synergi
polyalcohol
hand
antisept
sterillium
med
desderman
pure
abil
inactiv
hbv
quantit
suspens
test
importantli
hand
disinfect
demonstr
virucid
activ
readytous
concentr
inactiv
hbv
undetect
level
figur
residu
viru
detect
treatment
polyalcohol
hand
antisept
next
evalu
whether
dilut
commerci
antisept
affect
virucid
activ
product
dilut
alcoholbas
product
abrog
inactiv
properti
reach
reduct
sterillium
classic
pure
manorapid
synergi
figur
propos
guidelin
hand
hygien
healthcar
recommend
use
alcoholbas
hand
rub
formul
formul
ii
surgic
hygien
hand
disinfect
healthcar
set
reduc
transmiss
pathogen
hand
formul
base
ethanol
wherea
formul
ii
consist
determin
efficaci
formul
ii
hbv
incub
viral
particl
second
formul
final
concentr
rang
depict
supplementari
figur
viral
titer
tcid
ml
control
reduc
undetect
level
concentr
formul
wherea
concentr
formul
ii
yield
signific
reduct
infect
supplementari
figur
final
analyz
suscept
hbv
formul
comparison
envelop
virus
investig
previous
compar
analysi
inactiv
respons
curv
reveal
hbv
greater
stabil
hepat
c
viru
hcv
influenza
viru
middl
east
respiratori
syndrom
coronaviru
merscov
ebola
viru
ebov
modifi
vaccinia
viru
ankara
mva
supplementari
figur
chosen
test
viru
envelop
virus
european
guidelin
test
chemic
disinfect
antisept
human
medicin
studi
analyz
stabil
hbv
use
recent
develop
cell
cultur
system
fulli
suscept
permiss
hbv
infect
replic
high
titer
viru
stock
high
environment
stabil
hbv
observ
studi
also
previous
observ
vivo
model
system
bond
et
al
demonstr
hbvposit
human
plasma
dri
week
inocul
chimpanze
result
activ
infect
infect
system
base
human
hepatoma
cell
virus
gener
vitro
might
differ
primari
human
hepatocyt
patientderiv
viral
particl
aspect
howev
given
recent
progress
made
hbv
research
use
system
cell
culturederiv
hbv
particl
consid
best
tool
address
question
describ
howev
time
point
longterm
storag
plasma
ex
vivo
investig
hcv
anoth
bloodborn
viru
belong
famili
flavivirida
environment
stabil
much
lower
halflif
hour
day
regard
inactiv
profil
hbv
differ
alcohol
could
identifi
effect
alcohol
quantit
suspens
test
line
describ
hcv
concentr
test
alcohol
requir
virucid
activ
slightli
higher
requir
oftenus
dhbv
sidebysid
comparison
use
experiment
procedur
conduct
importantli
differ
alcoholbas
commerci
avail
hand
disinfect
abl
inactiv
hbv
exposur
second
suspens
test
dilut
product
abrog
suscept
hbv
practic
condit
hand
antisept
dilut
preclud
recommend
specif
product
two
whorecommend
formul
propos
alcoholbas
hand
rub
reduc
transmiss
pathogen
abl
complet
inactiv
hbv
importantli
comparison
envelop
virus
ebov
hcv
influenza
viru
merscov
mva
hbv
demonstr
highest
stabil
degre
suscept
differ
virus
formul
like
depend
specif
surfac
properti
lipophil
envelop
respect
viru
hbv
subvir
particl
display
fluid
bilay
membran
shown
strong
resist
freez
dri
howev
investig
requir
futur
ideal
serumderiv
hbv
analyz
phenomenon
detail
summari
first
systemat
investig
environment
stabil
hbv
suscept
differ
alcohol
hand
antisept
import
implic
manag
nosocomi
occup
exposur
hbv
propos
strict
complianc
establish
hygien
guidelin
mandatori
avoid
nosocomi
occup
hbv
infect
even
materi
contamin
hbv
sever
week
supplementari
materi
avail
journal
infecti
diseas
onlin
consist
data
provid
author
benefit
reader
post
materi
copyedit
sole
respons
author
question
comment
address
correspond
author
